BBLGHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 19 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Bone Biologics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (100): Smaller than most of the companies we track.
Momentum (2): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BBLG, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Apr 2023 | EF Hutton | Reiterates | Buy | $2.25 |
| 3 Apr 2023 | EF Hutton | Reiterates | Buy | $2.25 |
| 18 Oct 2022 | EF Hutton | Initiates | Buy | $2.25 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BBLG appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 18 Sept 2026, Bone Biologics Corp. returned −75.7% against +16.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 73% of US stocks
Cheaper than 89% of US stocks
Cheaper than 58% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 20% of US stocks
Higher than 12% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Bone Biologics Corp. has a market value of $1.4M and an enterprise value of −$2.6M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$2.9M.
Free cash flow in the twelve months to 30 June 2026: −$2.6M.
Trailing P/E: 0.1×; forward P/E: −0.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Bone Biologics Corp. employs 2 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Bone Biologics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Bone Biologics announced that six hospital sites in Australia are now under agreement to participate in its first-in-human pilot clinical trial of NB1, its rhNELL-1-based bone graft product for spinal fusion.
Why it matters — The expansion to six trial sites advances the clinical development of the company's lead spinal fusion product NB1, moving its first-in-human study forward.
Bone Biologics Corporation (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announced it will participate in the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026 at the Lotte New York Palace Hotel in New York City.
Why it matters — The company's participation in a major investment conference signals an opportunity for Bone Biologics to present its business to investors and the broader financial community.
Bone Biologics Corporation announced that the validated shelf life of its rhNELL-1 protein has been extended to 32 months. According to CEO Jeff Frelick, this gives the company greater flexibility in manufacturing, storing, and distributing rhNELL-1 as it prepares for pivotal-study scale.
Why it matters — For BBLG watchers, the longer validated shelf life signals progress toward pivotal-study readiness, supporting the company's manufacturing and distribution planning for its spine-fusion orthobiologic product.
As at 19 Sept 2026, Bone Biologics Corp. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (100 of 100).
No analyst covering Bone Biologics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BBLG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $12 over the next 12 months.
Bone Biologics Corp. returned -75.7% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Bone Biologics Corp is a clinical-stage medical device company focused on orthobiologic products for spinal fusion and bone regeneration. The company’s current work centers on NELL-1, a recombinant human protein used with demineralized bone matrix to support targeted bone healing in lumbar spinal fusion procedures.
The most recent item we track (GlobeNewsWire, 8 Sept 2026): "Bone Biologics Expands Trial Sites". Bone Biologics announced that six hospital sites in Australia are now under agreement to participate in its first-in-human pilot clinical trial of NB1, its rhNELL-1-based bone graft product for spinal fusion.
Bone Biologics Corp is a clinical-stage medical device company focused on orthobiologic products for spinal fusion and bone regeneration. The company’s current work centers on NELL-1, a recombinant human protein used with demineralized bone matrix to support targeted bone healing in lumbar spinal fusion procedures. Its product development is aimed at improving outcomes in skeletal repair, with applications that extend across spinal, orthopedic, reconstructive, neurosurgical, and sports medicine settings. Bone Biologics Corp operates in the healthcare technology and medical specialties space, where orthobiologics play an important role in supporting bone growth and repair during surgery. Headquartered in Burlington, Massachusetts, Bone Biologics Corp is positioned as a developer of regenerative solutions for surgeons and medical centers working with complex bone-related procedures.
CEO Mr. Jeffrey Frelick · 2 employees · United States · https://www.bonebiologics.com
